Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19
Aparisi et al.,
Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19,
medRxiv, doi:10.1101/2020.10.06.20207092 (Preprint)
Retrospective 654 hospitalized patients focused on low-density lipoprotein cholesterol levels, also showing results for HCQ with 605 HCQ patients, unadjusted 30 day mortality relative risk RR 0.37, p = 0.008.
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
risk of death, 63.0% lower, RR 0.37, p = 0.008, treatment 122 of 605 (20.2%), control 27 of 49 (55.1%), NNT 2.9.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Aparisi et al., 8 Oct 2020, prospective, Spain, preprint, 18 authors, average treatment delay 7.0 days.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.10.06.20207092; this version posted October 8, 2020. The copyright holder has placed this
preprint (which was not certified by peer review) in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse,
remix, or adapt this material for any purpose without crediting the original authors.
Low-density lipoprotein cholesterol levels are
associated with poor clinical outcomes in COVID-19
Álvaro Aparisi, MD1#; Carolina Iglesias-Echeverría, MD1; Cristina Ybarra-Falcón, MD1; Iván Cusácovich, MD, PhD3; Aitor
Uribarri MD, PhD1 ; Mario García-Gómez, MD1 ; Raquel Ladrón MD1; Raúl Fuertes ; MD⁴; Jordi Candela, MD1; Williams
Hinojosa, MD1; Carlos Dueñas, MD3; Roberto González, MD, PhD3; Leonor Nogales, MD5; Dolores Calvo MD6; Manuel
Carrasco-Moraleja, MSc1; J. Alberto San Román, MD, PhD1,2; Ignacio J.Amat-Santos, MD, PhD1,2 ; David Andaluz-Ojeda,
MD, PhD5*
¹Cardiology Department, Hospital Clínico Universitario, Valladolid, Spain
²CIBERCV, Cardiology Department, Hospital Clínico Universitario, Valladolid, Spain
3
Internal Medicine Deparment, Hospital Clínico Universitario de Valladolid, Spain
4
5
Medicine School, University of Valladolid, Valladolid, Spain
Intensive Care Unit Department, Hospital Clínico Universitario de Valladolid, Spain
6
Clinical analysis department, Hospital Clínico Universitario de Valladolid, Spain
Short title: LDL levels in COVID-19
Word count: 3,010
Abstract word count: 200
Conflicts of interest: None.
Financial sources: This work was partially funded by Gerencia Regional de Salud de Castilla y León under
grant number GRS COVID 111/A/20 and GRS COVID 108/A/20
Ethics of protocol: According to the Declaration of Helsinki, the local ethics committee approved this study.
*Corresponding author:
David Andaluz Ojeda, MD, Ph.D.
Intensive Care Department.
Hospital Clínico Universitario de Valladolid, Spain.
Ramón y Cajal 3. 47005. Valladolid. Spain.
Telephone. 0034 983 42 00 26. Fax. 0034 983 25 53 05
e-mail: dandaluz@saludcastillayleon.es
1
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2020.10.06.20207092; this version posted October 8, 2020. The copyright holder has placed this
preprint (which was not certified by peer review) in the Public Domain. It is no longer restricted by copyright. Anyone can legally share, reuse,
remix, or adapt this material for any purpose without crediting the original authors.
STRUCTURED ABSTRACT
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the sole causative
agent of coronavirus infectious disease-19 (COVID-19).
Methods: We performed a retrospective single-center study of consecutively admitted patients
between March 1st and May 15th, 2020, with a definitive diagnosis of SARS-CoV-2 infection. The
primary end-point was to evaluate the association of lipid markers with 30-days all-cause mortality in
COVID-19.
Results: A total of 654 patients were enrolled, with an estimated 30-day mortality of 22.8% (149
patients). Non-survivors had lower total cholesterol (TC) and low-density lipoprotein cholesterol
(LDL-c) levels during the entire course of the disease with complete resolution among survivors.
Both showed a significant inverse correlation with inflammatory markers and a positive correlation
with lymphocyte count. In a multivariate analysis, LDL-c ≤..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit